Neurocrine Biosciences IncNASDAQ:NBIX
- LAST PRICE139.4300
- TODAY'S CHANGE (%)-1.1200 (-0.7969%)
- Bid / Lots137.0200/ 1
- Ask / Lots145.0000/ 1
- Open / Previous Close139.0000 / 140.5500
- Day Range
- 52 Week Range
- Volume1,173,792
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NBIX |
|---|---|---|
| 09:32 ET | 48283 | 138.875 |
| 09:34 ET | 20937 | 138.715 |
| 09:36 ET | 21827 | 140.02 |
| 09:38 ET | 930 | 140.2 |
| 09:39 ET | 1300 | 141.08 |
| 09:41 ET | 21920 | 141.19 |
| 09:43 ET | 12042 | 141.205 |
| 09:45 ET | 16600 | 142.82 |
| 09:48 ET | 100769 | 144.55 |
| 09:50 ET | 18826 | 144.675 |
| 09:52 ET | 17142 | 143.56 |
| 09:54 ET | 1982 | 143.02 |
| 09:56 ET | 4800 | 142.6837 |
| 09:57 ET | 8097 | 142.085 |
| 09:59 ET | 1653 | 141.97 |
| 10:01 ET | 2300 | 140.9101 |
| 10:03 ET | 1025 | 140.92 |
| 10:06 ET | 69065 | 140.905 |
| 10:08 ET | 700 | 141.35 |
| 10:10 ET | 4100 | 141.47 |
| 10:12 ET | 1900 | 141.515 |
| 10:14 ET | 3932 | 140.9 |
| 10:15 ET | 1496 | 140.66 |
| 10:17 ET | 700 | 141.03 |
| 10:19 ET | 3269 | 141.05 |
| 10:21 ET | 1405 | 141.055 |
| 10:24 ET | 6607 | 140.92 |
| 10:26 ET | 1961 | 141.13 |
| 10:28 ET | 600 | 141.14 |
| 10:30 ET | 6359 | 141.3 |
| 10:32 ET | 2383 | 141.45 |
| 10:33 ET | 3250 | 141.36 |
| 10:35 ET | 2074 | 141.08 |
| 10:37 ET | 6100 | 140.11 |
| 10:39 ET | 4058 | 140.07 |
| 10:42 ET | 700 | 140.13 |
| 10:44 ET | 2500 | 140.05 |
| 10:46 ET | 8145 | 139.69 |
| 10:48 ET | 3939 | 139.98 |
| 10:50 ET | 5235 | 140.19 |
| 10:51 ET | 650 | 140.13 |
| 10:53 ET | 1615 | 140.15 |
| 10:55 ET | 953 | 140.165 |
| 10:57 ET | 2600 | 140 |
| 11:00 ET | 700 | 140.02 |
| 11:02 ET | 1500 | 139.81 |
| 11:04 ET | 2400 | 139.895 |
| 11:06 ET | 4200 | 139.74 |
| 11:08 ET | 6165 | 139.955 |
| 11:09 ET | 500 | 139.985 |
| 11:11 ET | 1800 | 139.985 |
| 11:13 ET | 1900 | 139.985 |
| 11:15 ET | 1700 | 139.74 |
| 11:18 ET | 2117 | 139.64 |
| 11:20 ET | 420 | 139.6 |
| 11:22 ET | 2290 | 139.69 |
| 11:24 ET | 400 | 139.69 |
| 11:26 ET | 600 | 139.61 |
| 11:27 ET | 1100 | 140.075 |
| 11:29 ET | 1300 | 140.1 |
| 11:31 ET | 2100 | 140.465 |
| 11:33 ET | 400 | 140.565 |
| 11:36 ET | 1300 | 140.435 |
| 11:38 ET | 750 | 140.44 |
| 11:40 ET | 400 | 140.44 |
| 11:42 ET | 1901 | 140.45 |
| 11:44 ET | 1625 | 140.655 |
| 11:45 ET | 2499 | 140.83 |
| 11:47 ET | 400 | 140.84 |
| 11:49 ET | 300 | 140.845 |
| 11:51 ET | 1300 | 140.52 |
| 11:54 ET | 100 | 140.525 |
| 11:56 ET | 400 | 140.495 |
| 11:58 ET | 1791 | 140.3 |
| 12:00 ET | 400 | 140.43 |
| 12:02 ET | 1081 | 140.465 |
| 12:03 ET | 570 | 140.27 |
| 12:05 ET | 700 | 140.26 |
| 12:07 ET | 8018 | 140.49 |
| 12:09 ET | 2000 | 140.83 |
| 12:12 ET | 300 | 140.775 |
| 12:14 ET | 200 | 140.79 |
| 12:16 ET | 1529 | 140.895 |
| 12:18 ET | 637 | 140.915 |
| 12:20 ET | 5945 | 140.6125 |
| 12:21 ET | 300 | 140.63 |
| 12:23 ET | 200 | 140.63 |
| 12:25 ET | 1600 | 140.895 |
| 12:27 ET | 200 | 140.885 |
| 12:30 ET | 400 | 140.9 |
| 12:32 ET | 1404 | 140.785 |
| 12:34 ET | 300 | 140.8 |
| 12:36 ET | 400 | 140.81 |
| 12:38 ET | 2938 | 141.195 |
| 12:39 ET | 733 | 141.255 |
| 12:41 ET | 1500 | 141.05 |
| 12:43 ET | 300 | 141.07 |
| 12:45 ET | 1668 | 140.955 |
| 12:48 ET | 600 | 141.015 |
| 12:50 ET | 600 | 141.02 |
| 12:52 ET | 510 | 141.04 |
| 12:54 ET | 1700 | 140.985 |
| 12:56 ET | 2402 | 141.1106 |
| 12:57 ET | 600 | 141.035 |
| 12:59 ET | 6199 | 141.005 |
| 01:01 ET | 30374 | 141.255 |
| 01:03 ET | 2245 | 141.39 |
| 01:06 ET | 1500 | 141.54 |
| 01:08 ET | 1000 | 141.37 |
| 01:10 ET | 100 | 141.36 |
| 01:12 ET | 300 | 141.27 |
| 01:14 ET | 700 | 141.34 |
| 01:15 ET | 3100 | 141.515 |
| 01:17 ET | 4360 | 141.605 |
| 01:19 ET | 2306 | 141.495 |
| 01:21 ET | 800 | 141.505 |
| 01:24 ET | 100 | 141.475 |
| 01:26 ET | 2200 | 141.31 |
| 01:28 ET | 100 | 141.4172 |
| 01:30 ET | 300 | 141.35 |
| 01:32 ET | 411 | 141.22 |
| 01:33 ET | 1000 | 141.07 |
| 01:35 ET | 499 | 141.08 |
| 01:37 ET | 900 | 140.91 |
| 01:39 ET | 2200 | 140.71 |
| 01:42 ET | 1300 | 140.735 |
| 01:44 ET | 2818 | 140.565 |
| 01:46 ET | 3498 | 140.53 |
| 01:48 ET | 1373 | 140.66 |
| 01:50 ET | 2000 | 140.6 |
| 01:51 ET | 100 | 140.605 |
| 01:53 ET | 100 | 140.6 |
| 01:55 ET | 349 | 140.52 |
| 01:57 ET | 5960 | 140.785 |
| 02:00 ET | 7740 | 140.77 |
| 02:02 ET | 1669 | 140.625 |
| 02:04 ET | 200 | 140.54 |
| 02:06 ET | 8928 | 140.49 |
| 02:08 ET | 15653 | 140.395 |
| 02:09 ET | 100 | 140.415 |
| 02:13 ET | 200 | 140.41 |
| 02:15 ET | 200 | 140.2901 |
| 02:18 ET | 1510 | 140.24 |
| 02:20 ET | 1700 | 140.31 |
| 02:22 ET | 1100 | 139.85 |
| 02:24 ET | 604 | 139.77 |
| 02:26 ET | 2506 | 139.95 |
| 02:27 ET | 100 | 139.84 |
| 02:29 ET | 2644 | 140.005 |
| 02:33 ET | 800 | 140.005 |
| 02:36 ET | 1100 | 139.76 |
| 02:38 ET | 600 | 139.745 |
| 02:40 ET | 100 | 139.845 |
| 02:42 ET | 100 | 139.855 |
| 02:44 ET | 300 | 139.77 |
| 02:47 ET | 1684 | 139.93 |
| 02:49 ET | 1100 | 140.05 |
| 02:51 ET | 1935 | 139.9275 |
| 02:54 ET | 1449 | 139.945 |
| 02:56 ET | 800 | 139.925 |
| 02:58 ET | 1700 | 139.845 |
| 03:00 ET | 1200 | 140 |
| 03:02 ET | 600 | 139.965 |
| 03:03 ET | 711 | 139.85 |
| 03:07 ET | 1513 | 139.785 |
| 03:09 ET | 300 | 139.85 |
| 03:12 ET | 1315 | 139.865 |
| 03:14 ET | 2300 | 139.92 |
| 03:16 ET | 2360 | 139.7717 |
| 03:20 ET | 2405 | 139.58 |
| 03:21 ET | 3945 | 139.66 |
| 03:23 ET | 300 | 139.745 |
| 03:25 ET | 700 | 139.86 |
| 03:27 ET | 975 | 139.845 |
| 03:30 ET | 2100 | 139.99 |
| 03:32 ET | 920 | 140.17 |
| 03:34 ET | 732 | 140.205 |
| 03:36 ET | 3103 | 139.95 |
| 03:38 ET | 2000 | 139.85 |
| 03:39 ET | 1800 | 139.5 |
| 03:41 ET | 1600 | 139.39 |
| 03:43 ET | 1300 | 139.33 |
| 03:45 ET | 6677 | 138.97 |
| 03:48 ET | 2920 | 138.81 |
| 03:50 ET | 10000 | 138.65 |
| 03:52 ET | 3878 | 138.72 |
| 03:54 ET | 10538 | 138.69 |
| 03:56 ET | 10198 | 139.34 |
| 03:57 ET | 7353 | 139.46 |
| 03:59 ET | 111319 | 139.43 |
May 21, 2024
Neurocrine Biosciences Announces Publication of Phase 3 KINECT(R)-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA(R) (valbenazine) Capsules, from 4:05PM ET on Tuesday May 21, 2024 by Dow Jones
4:05PM ET on Tuesday May 21, 2024 by Dow Jones
May 15, 2024
DJ S&P 500 Futures Steady In Premarket Trading; Monday.Com, Nextracker Lead, from 7:31AM ET on Wednesday May 15, 2024 by Dow Jones
7:31AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
Neurocrine Biosciences Presented Baseline Data from the CAHtalyst(TM) Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024, from 8:30AM ET on Tuesday May 14, 2024 by Dow Jones
8:30AM ET on Tuesday May 14, 2024 by Dow JonesDJ Neurocrine Initiated at Outperform by Evercore ISI Group, from 5:26AM ET on Tuesday May 14, 2024 by Dow Jones
5:26AM ET on Tuesday May 14, 2024 by Dow Jones
May 13, 2024
DJ S&P 500 Futures Rise In Premarket Trading; GameStop, Squarespace Lead, from 7:31AM ET on Monday May 13, 2024 by Dow Jones
7:31AM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neurocrine Biosciences Inc | 14.1B | 38.3x | +62.04% |
Medpace Holdings Inc | 12.3B | 39.7x | +35.10% |
Biomarin Pharmaceutical Inc | 14.7B | 72.4x | --- |
Qiagen NV | 10.0B | 28.5x | +12.66% |
United Therapeutics Corp | 12.2B | 13.1x | +8.22% |
Alnylam Pharmaceuticals Inc | 18.9B | -55.7x | --- |
Company Information
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Contact Information
- Headquarters
- 6027 EDGEWOOD BEND COURTSAN DIEGO, CA, United States 92130
- Phone
- 858-617-7600
- Fax
- 858-617-7602
Executives
- Non-Executive Independent Chairman of the Board
- William Rastetter
- Chief Executive Officer, Director
- Kevin Gorman
- Chief Financial Officer
- Matthew Abernethy
- Chief Human Resource Officer
- Julie Cooke
- Chief Scientific Officer
- Jude Onyia
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.1B |
|---|---|
Revenue (TTM) | $2.0B |
Shares Outstanding | 100.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.36 |
EPS | $3.64 |
Book Value | $22.61 |
P/E Ratio | 38.3x |
Price/Sales (TTM) | 7.1 |
Price/Cash Flow (TTM) | 36.1x |
Operating Margin | 23.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
